Gilead Sciences Inc GIS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Gilead's HIV-prevention drug cut infections by 96%, boosting stock
-
Gilead, Genesis Therapeutics to Use AI to Discover Novel Therapies
-
Gilead Sciences Currently Up Nine Consecutive Days, on Pace for Longest Winning Streak Since July 2023 — Data Talk
-
Gilead Sciences Currently Up Eight Consecutive Days, on Pace for Longest Winning Streak Since July 2023 — Data Talk
-
Gilead Sciences Receives Accelerated Approval from FDA
-
Gilead Sciences posts higher Q2 profit and revenue on increased sales
-
Gilead Sciences Posts Higher 2Q Profit, Revenue on Increased Sales
-
Gilead Sciences Chief Medical Officer to Step Down
Trading Information
- Previous Close Price
- $73.99
- Day Range
- $74.48–75.21
- 52-Week Range
- $46.26–71.67
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $93.55 Bil
- Volume/Avg
- 13 / 1,183
Key Statistics
- Price/Earnings (Normalized)
- 17.07
- Price/Sales
- 3.60
- Dividend Yield (Trailing)
- 3.78%
- Dividend Yield (Forward)
- 3.74%
- Total Yield
- 4.47%
Company Profile
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 18,000
- Website
- https://www.gilead.com
Competitors
Valuation
|
Metric
|
GIS
|
MRK
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 17.07 | 17.37 | 17.93 |
Price/Book Value | 5.40 | 6.58 | 50.00 |
Price/Sales | 3.60 | 4.61 | 6.18 |
Price/Cash Flow | 8.66 | 15.37 | 18.20 |
Price/Earnings
GIS
MRK
ABBV
Financial Strength
|
Metric
|
GIS
|
MRK
|
ABBV
|
|---|---|---|---|
Quick Ratio | 0.69 | 0.88 | 0.59 |
Current Ratio | 1.14 | 1.47 | 0.81 |
Interest Coverage | 2.58 | 13.07 | 3.51 |
Quick Ratio
GIS
MRK
ABBV
Profitability
|
Metric
|
GIS
|
MRK
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 9.97% | 15.46% | 13.66% |
Return on Equity (Normalized) | 28.96% | 41.15% | 189.99% |
Return on Invested Capital (Normalized) | 14.56% | 22.92% | 27.06% |
Return on Assets
GIS
MRK
ABBV
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Hzgfykqdh | Gddw | $818.8 Bil | |||
| Johnson & Johnson
JNJ
| Yghzjmkk | Hsl | $388.5 Bil | |||
| AbbVie Inc
ABBV
| Zwydtsyxz | Cwdk | $339.0 Bil | |||
| Merck & Co Inc
MRK
| Dkpvmqpd | Wxxt | $286.7 Bil | |||
| Roche Holding AG ADR
RHHBY
| Gjllddkntn | Fprz | $255.9 Bil | |||
| AstraZeneca PLC ADR
AZN
| Zntnvnrbg | Zvrr | $241.9 Bil | |||
| Novartis AG ADR
NVS
| Gnhlzltm | Xgkqf | $233.0 Bil | |||
| Amgen Inc
AMGN
| Nnzvxtwwqp | Fnq | $171.5 Bil | |||
| Pfizer Inc
PFE
| Gkdqvbn | Blsx | $164.2 Bil | |||
| Sanofi SA ADR
SNY
| Pfjjsywxk | Qckk | $142.8 Bil |
United States